In development over the last 12 months, UK-based company Evocutis has developed its LabSkin in vitro skin models, to support antimicrobial and skin microbe balancing product claims, which could, in time, replace clinical trials.
Speaking at the Microbiota event held in Paris, chief scientific officer, Richard Bojar, told CosmeticsDesign-Europe.com that the development of the skin equivalent could potentially replace clinical trials, although he added this was “probably a long way off”.
Evocutis, which focuses on advanced laboratory and clinical evaluations of skin care products for the cosmetic markets, developed its animal-replacement technology as it emulates living skin and is a high-value research and product testing tool for the cosmetic and healthcare industries.
“LabSkin provides a unique living skin surface which is validated for microbial applications and can simultaneously provide information on irritation, penetration, barrier function and skin structure. This makes it a valuable tool for the development of innovative products,” he said.
Bojar explained that the technology, made of two types of cell, is suitable for testing any kind of application.
“It’s suitable for soluble compounds… you can put a solution on it, a suspension, you can put a full formulation on… because it’s a strong piece of skin; you can rub it with your finger, or apply cream to it as you would to your face.”